Evidence map›Paper›PMID 42182291›Full record

ArticlebioRxiv : the preprint server for biology2026

Activity of a three-phage combination against

S Janssen, S E Larsen, M Pozuelo Torres, M Beldjenna, C A Guerrero Bustamante, I Florian, T Smytheman, T Guo, R C van Wijk, G F Hatfull and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

S JanssenRadboud University Medical Centre, Department of Medical Microbiology, Community for Infectious Diseases & Research Institute of Medical Innovation, Nijmegen, The Netherlands.ORCID 0000-0003-0966-3233
S E LarsenSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA.ORCID 0000-0001-5034-9727
M Pozuelo TorresRadboud University Medical Centre, Department of Medical Microbiology, Community for Infectious Diseases & Research Institute of Medical Innovation, Nijmegen, The Netherlands.
M BeldjennaSystems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands.
C A Guerrero BustamanteUniversity of Pittsburgh, Pittsburgh, United States.
I FlorianUniversity of Pittsburgh, Pittsburgh, United States.
T SmythemanSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA.
T GuoSystems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands.ORCID 0000-0002-7892-6220
R C van WijkSystems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands.
G F HatfullUniversity of Pittsburgh, Pittsburgh, United States.ORCID 0000-0002-6705-6821
A H DiaconTASK, Cape Town, South Africa.
R N ColerSeattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA.ORCID 0000-0001-6974-5666
J van IngenRadboud University Medical Centre, Department of Medical Microbiology, Community for Infectious Diseases & Research Institute of Medical Innovation, Nijmegen, The Netherlands.ORCID 0000-0002-0581-2003

Funding

Seattle Tuberculosis Research Advancement CenterP30AI168034 · NIAID · UNIVERSITY OF WASHINGTON · PI Rhea N Coler, CHETAN SESHADRI · 2022 to 2026
$6.3M
Dynamics of viral host range evolutionR01GM116884 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HATFULL, GRAHAM F. · 2015 to 2019
$2.0M
Advancing mycobacteriophage aerosol for prevention of pulmonary infectionsR21AI156807 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI COLER, RHEA N, LARSEN, SASHA E. · 2021 to 2022
$503k
NIAID NIH HHS P30 AI168034NIAID NIH HHS R21 AI156807NIGMS NIH HHS R01 GM116884
6 · The paper itself

Abstract

Phage therapy offers promise to combat antimicrobial resistance, including drug-resistant tuberculosis (TB). Understanding phage activity against

Indexed as

Mycobacteriophagesphage therapypreclinicaltuberculosis

Identifiers

PMID42182291
PMCPMC13192880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.